Publicacións en colaboración con investigadores/as de The Bristol-Myers Squibb Children's Hospital (6)

2015

  1. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: New analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE)

    Arthritis Research and Therapy, Vol. 17, Núm. 1

  2. Long-Term Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept for Up to Seven Years

    Arthritis and Rheumatology, Vol. 67, Núm. 10, pp. 2759-2770

  3. Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis

    Annals of the Rheumatic Diseases, Vol. 74, Núm. 3, pp. 564-568

2011

  1. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-Year outcomes

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 11, pp. 1949-1956

2010

  1. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis

    Arthritis and Rheumatism, Vol. 62, Núm. 6, pp. 1792-1802

2009

  1. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

    Annals of the Rheumatic Diseases, Vol. 68, Núm. 12, pp. 1870-1877